MA55884A - Domaines variants pour la multimérisation de protéines et leur séparation - Google Patents

Domaines variants pour la multimérisation de protéines et leur séparation

Info

Publication number
MA55884A
MA55884A MA055884A MA55884A MA55884A MA 55884 A MA55884 A MA 55884A MA 055884 A MA055884 A MA 055884A MA 55884 A MA55884 A MA 55884A MA 55884 A MA55884 A MA 55884A
Authority
MA
Morocco
Prior art keywords
multimerization
proteins
separation
variant domains
domains
Prior art date
Application number
MA055884A
Other languages
English (en)
Inventor
Richard Bonneau
Kruif Cornelis Adriaan De
Peter Brian Silverman
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MA55884A publication Critical patent/MA55884A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA055884A 2019-05-09 2020-05-08 Domaines variants pour la multimérisation de protéines et leur séparation MA55884A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19173633 2019-05-09

Publications (1)

Publication Number Publication Date
MA55884A true MA55884A (fr) 2022-03-16

Family

ID=66476558

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055884A MA55884A (fr) 2019-05-09 2020-05-08 Domaines variants pour la multimérisation de protéines et leur séparation

Country Status (16)

Country Link
US (1) US20210054049A1 (fr)
EP (1) EP3966238A2 (fr)
JP (2) JP7760377B2 (fr)
KR (1) KR20220017909A (fr)
CN (2) CN114702587A (fr)
AR (1) AR118898A1 (fr)
AU (2) AU2020268684C1 (fr)
BR (1) BR112021022405A2 (fr)
CA (1) CA3139402A1 (fr)
IL (1) IL287928A (fr)
MA (1) MA55884A (fr)
MX (1) MX2021013646A (fr)
PH (1) PH12021552833A1 (fr)
SG (1) SG11202112399PA (fr)
TW (1) TW202108613A (fr)
WO (1) WO2020226502A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202009036YA (en) * 2018-03-30 2020-10-29 Merus Nv Multivalent antibody
JP2024500747A (ja) * 2020-12-18 2024-01-10 キニクサ ファーマシューティカルズ， リミテッド タンパク質組成物ならびにそれを産生及び使用するための方法
IL321671A (en) 2022-12-27 2025-08-01 Merus Nv Method for generating bispecific proteins
TW202544033A (zh) 2024-04-15 2025-11-16 荷蘭商美勒斯公司 Ｃｄ３結合結構域
WO2025230409A1 (fr) 2024-04-30 2025-11-06 Merus N.V. Conjugués anticorps-médicament multispécifiques
WO2025230410A1 (fr) 2024-04-30 2025-11-06 Merus N.V. Conjugués anticorps-médicament multispécifiques
WO2026013015A1 (fr) 2024-07-09 2026-01-15 Merus N.V. Fractions de liaison multispécifiques comprenant des domaines de liaison à calr et cd3
WO2026018064A1 (fr) 2024-07-16 2026-01-22 Merus N.V. Conjugués anticorps-médicament multi-médicament multispécifiques

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
US7135287B1 (en) * 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US6680209B1 (en) * 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
US7803913B2 (en) * 2002-05-06 2010-09-28 The United States Of America As Represented By The Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
EP2314629B2 (fr) 2002-07-18 2022-11-16 Merus N.V. Production recombinante de mélanges d'anticorps
HRP20050986A2 (en) * 2002-08-19 2006-11-30 Abgenix Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
WO2005092925A2 (fr) * 2004-03-24 2005-10-06 Xencor, Inc. Variantes d'immunoglobuline a l'exterieur de la region fc
CA2595169A1 (fr) * 2005-01-12 2006-07-20 Xencor, Inc. Anticorps et proteines de fusion fc a immunogenicite modifiee
EP2009101B1 (fr) * 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Procede de modification d'anticorps pour purifier un anticorps bispecifique
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
CN101874042B9 (zh) * 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
RU2731084C2 (ru) 2008-06-27 2020-08-28 Мерюс Н.В. Продуцирующие антитела млекопитающие, не являющиеся человеком
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
AU2012235758B2 (en) * 2011-03-25 2015-05-07 IGI Therapeutics SA Hetero-dimeric immunoglobulins
TW201817744A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
CA3182462A1 (fr) * 2011-10-10 2013-04-18 Xencor, Inc. Procede de purification d'anticorps
ES2732712T3 (es) * 2011-10-31 2019-11-25 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno que tiene una conjugación regulada entre la cadena pesada y la cadena ligera
DK2838918T3 (da) 2012-04-20 2019-08-12 Merus Nv Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
CN104045714B (zh) * 2013-03-14 2019-01-11 南京金斯瑞生物科技有限公司 曲妥珠单抗突变体IgG及其应用
EP3936521B1 (fr) 2013-03-15 2026-02-11 Xencor, Inc. Protéines hétérodimériques
EP3786186A1 (fr) 2014-02-28 2021-03-03 Merus N.V. Anticorps qui se lient aux egfr et erbb3
CN106573986A (zh) * 2014-07-29 2017-04-19 豪夫迈·罗氏有限公司 多特异性抗体
MA41375A (fr) * 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
CA3026991A1 (fr) * 2016-06-10 2017-12-14 Eisai R&D Management Co., Ltd. Immunoglobulines conjuguees a la lysine
WO2017218698A1 (fr) * 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Anticorps à domaines ch2 modifiés, compositions les contenant et leurs procédés d'utilisation
MX2020000055A (es) 2017-07-06 2020-08-06 Merus Nv Anticuerpos biespecificos antiproteina 1 de muerte celular programada (pd-1) -anti inmunoglobulina de celulas t y dominio de mucina que contiene -3 (tim-3).
EA202090005A1 (ru) 2017-07-06 2020-06-18 Мерус Н.В. Антитела, модулирующие биологическую активность, проявляемую клеткой
CA3068929A1 (fr) 2017-07-06 2019-01-10 Merus N.V. Molecules de liaison permettant de moduler l'activite biologique exprimee par une cellule
SI3665198T1 (sl) 2017-08-09 2025-06-30 Merus N.V. Protitelesa, ki vežejo egfr in cmet
WO2019148410A1 (fr) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anticorps anti-pd-1
WO2019148412A1 (fr) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anticorps bispécifiques anti-pd-1/lag3
SG11202009036YA (en) 2018-03-30 2020-10-29 Merus Nv Multivalent antibody
CN110272495A (zh) * 2019-06-11 2019-09-24 南京华岩生物技术有限公司 一种能结合两种抗原的双特异性结合的免疫球蛋白及其用途

Also Published As

Publication number Publication date
TW202108613A (zh) 2021-03-01
AR118898A1 (es) 2021-11-10
BR112021022405A2 (pt) 2022-04-19
AU2020268684C1 (en) 2026-04-02
JP2022534674A (ja) 2022-08-03
EP3966238A2 (fr) 2022-03-16
CN114430745A (zh) 2022-05-03
US20210054049A1 (en) 2021-02-25
CA3139402A1 (fr) 2020-11-12
CN114702587A (zh) 2022-07-05
AU2020268684A1 (en) 2021-12-09
NZ782091A (en) 2025-08-29
SG11202112399PA (en) 2021-12-30
WO2020226502A2 (fr) 2020-11-12
AU2020268684B2 (en) 2025-07-03
IL287928A (en) 2022-01-01
WO2020226502A9 (fr) 2022-03-03
JP2025120179A (ja) 2025-08-15
MX2021013646A (es) 2022-01-31
WO2020226502A3 (fr) 2021-02-04
JP7760377B2 (ja) 2025-10-27
PH12021552833A1 (en) 2023-01-16
KR20220017909A (ko) 2022-02-14
AU2025208511A1 (en) 2025-08-14

Similar Documents

Publication Publication Date Title
EP3455218A4 (fr) Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles
EP3454856A4 (fr) Dégronimères hétérocycliques pour la dégradation de protéines cibles
IL287928A (en) Variant sites for multimerization of proteins and their separation
EP3337819C0 (fr) Méthode de purification pour la production de polypeptides recombinants utilisant fkpa
EP3810196A4 (fr) Polypeptides cycliques pour l'inhibition de la pcsk9
EP3411056A4 (fr) Compositions pour lier des domaines de liaison à l'adn et des domaines de clivage
EP3794151A4 (fr) Souches modifiées sec pour sécrétion améliorée de protéines recombinantes
EP3935083A4 (fr) Anticorps reconnaissant la protéine tau
EP3810178A4 (fr) Polypeptides cycliques pour l'inhibition de la pcsk9
EP3328429A4 (fr) Peptides et anticorps pour l'élimination de biofilms
EP3810176A4 (fr) Polypeptides cycliques pour l'inhibition de la pcsk9
EP3893916A4 (fr) Constructions de protéines de fusion pour une maladie associée au complément
EP3801920A4 (fr) Système centrifuge pour séparer des cellules en suspension
EP3572507A4 (fr) Procédé d'expression pour protéine recombinante d'haemocoagulase acutus
MA53498A (fr) Production de protéines recombinantes
EP3997239A4 (fr) Traitement de séparation et de quantification de protéines par électrophorèse capillaire
EP3638794A4 (fr) Construction multigénique pour l'expression de protéine immunomodulatrices et méthodes d'utilisation
EP3883950A4 (fr) Protéines pour bloquer la libération de neurotransmetteurs
SI3818078T1 (sl) Postopki za proizvodnjo rekombinantnih proteinov
IL288090A (en) Expression of antigen-binding proteins in the nervous system
EP3600418A4 (fr) Inhibition de la protéine 5 liée au récepteur de lipoprotéine de faible densité, qui supprime la formation de tumeur
EP3801485A4 (fr) Procédés de purification de protéines et de peptides
EP3773644A4 (fr) Protéines pour le traitement de troubles de la fonction de barrière épithéliale
MA52148A (fr) Peptides chimères pour administration d'antisens
EP3890771C0 (fr) Procédé de réduction des taux de protéine tau de liaison aux microtubules neuronaux